OneSource Specialty Pharma Ltd
OneSource Speci. | 544292
Share Price Chart - OneSource Specialty Pharma Ltd
Stock Performance
Ratios
About Company
- Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of Inbiopro Solutions Private Limited' dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore
- The Company name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies
- The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021,
- Subsequently, the name was changed to its present Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore
- In FY 2024-25, a Scheme of Arrangement amongst Strides Pharma Science Limited, Steriscience Specialties Private Limited and the Company and their respective shareholders and creditors was implemented on November 14, 2024
- Prior to the Scheme of Arrangement, Strides Pharma Science Limited, Steriscience Specialties Private Limited were involved in the businesses of biologics and DDC, soft gelatin capsule and injectables business, respectively
- Pursuant to the Scheme, Strides Pharma Science Limited, Steriscience Specialties Private Limited got transferred / demerged to and vested with the Company as a going concern effective on April 1, 2024 and the Scheme was made effective from November 27, 2024 with the Registrar of Companies
- In accordance with the Scheme of Arrangement, 11,44,36,021 Equity Shares of Re
- 1/- each have been allotted and issued
- At present, Company is engaged in the research, development, manufacture and commercialisation of biological drug products in various injectable formats
Research Calls
Technical Indicators
Pivot Points
Volume Analysis
Growth Rate
All figures in ₹ Crores
No Information Available
No shareholding data available at this time.
News
No Information Available
Peers
#IndiaInvests
Trusted by 2.5 lac + Indians for their wealth-building needs
Invest in stocks with ease
Open your account in less than 10 mins*
By proceeding, you agree to all T&C *
Top Gainers
Frequently Asked Questions
What is Share Price of OneSource Specialty Pharma Ltd?
The current share price of OneSource Specialty Pharma Ltd (OneSource Speci.) is ₹1626.90. This price reflects the latest market valuation and is updated in real-time during trading hours.
What is the P/E Ratio of OneSource Specialty Pharma Ltd?
The Price-to-Earnings (P/E) ratio of OneSource Specialty Pharma Ltd is 1626.90. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.
What is the 52-week high and low of OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd has a 52-week high of ₹2088.00 and a 52-week low of ₹1057.00. This range shows the stock's price volatility over the past year.
What is the Dividend Yield of OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd offers a dividend yield of 0.00%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.
What is the EPS of OneSource Specialty Pharma Ltd?
The Earnings Per Share (EPS) of OneSource Specialty Pharma Ltd is ₹-5.59. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.
What is the ROE of OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd has a Return on Equity (ROE) of 3.22%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.
Disclaimer:
Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.
